

AMENDMENTS TO THE CLAIMS

1.-127. (Canceled)

128. (**Currently amended**) A vaccine composition for vaccinating dogs comprising a coronavirus having an S protein with at least 75% amino acid identity with CRCV BCV S protein, or a coronavirus protein having at least 75% amino acid identity with a CRCV BCV protein or an immunogenic fragment thereof, or a nucleic acid encoding said coronavirus protein or immunogenic fragment thereof.

129. (**Previously presented**) A vaccine composition according to Claim 128 wherein the coronavirus protein is a BCV, HCV, HEV or CRCV protein, or a modification thereof.

130. (**Previously presented**) A vaccine composition according to Claim 128 wherein the coronavirus protein is an S protein.

131. (**Currently amended**) A vaccine composition according to Claim 130 wherein the S protein is selected from the group consisting of:

- a coronavirus Spike (S) protein, or fragment thereof, having at least 75% amino acid sequence identity with the CRCV S protein whose amino acid sequence is listed in Figure 4, and comprising at least one of the canine respiratory coronavirus (CRCV)-specific amino acids listed in Table 1;

- a coronavirus S protein that comprises the amino acid sequence listed in Figure 4, or a variant thereof with at least 97% amino acid sequence identity with the sequence listed in Figure 4;

- a BCV S protein;

- an HCV S protein; and

- an HEV S protein, or an immunogenic fragment thereof.

132.-133. (Canceled)

134. (**Currently amended**) A vaccine composition according to Claim 128 wherein the coronavirus is selected from the group consisting of BCV, HCV, HEV and CRCV, or a modification thereof.

135. (**Previously presented**) A vaccine composition according to Claim 128 and also comprising a pharmaceutically acceptable adjuvant.

136. **(Previously presented)** A vaccine composition according to Claim 128 further comprising any one or more of:

(a) an agent capable of raising an immune response in a dog against canine parainfluenza virus (CPIV);

(b) an agent capable of raising an immune response in a dog against canine adenovirus type 2 (CAV-2);

(c) an agent capable of raising an immune response in a dog against canine herpesvirus (CHV); and

(d) an agent capable of raising an immune response in a dog against *Bordetella bronchiseptica* (*B. bronchiseptica*).

137.-143. **(Canceled)**

144. **(Withdrawn)** A method of vaccinating a dog against CRCV, the method comprising administering to the dog a vaccine composition according to Claim 128.

145.-163. **(Canceled)**

164. **(New)** The vaccine composition according to Claim 128, wherein said coronavirus is inactivated.

165. **(New)** The vaccine composition according to Claim 128, wherein said coronavirus is attenuated.